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Abstract
Background: Leukocyte recruitment across blood vessels is fundamental to immune surveillance
and inflammation. Lymphocyte homing to peripheral lymph nodes is mediated by the adhesion
molecule, L-selectin, which binds to sulfated carbohydrate ligands on high endothelial venules
(HEV). These glycoprotein ligands are collectively known as peripheral node addressin (PNAd), as
defined by the function-blocking monoclonal antibody known as MECA-79. The sulfation of these
ligands depends on the action of two HEV-expressed N-acetylglucosamine 6-O-sulfotransferases:
GlcNAc6ST-2 and to a lesser degree GlcNAc6ST-1. Induction of PNAd has also been shown to
occur in a number of human inflammatory diseases including rheumatoid arthritis (RA).
Results: In order to identify an animal model suitable for investigating the role of PNAd in chronic
inflammation, we examined the expression of PNAd as well as GlcNAc6ST-1 and -2 in collagen-
induced arthritis in mice. Here we show that PNAd is expressed in the vasculature of arthritic
synovium in mice immunized with collagen but not in the normal synovium of control animals. This
de novo expression of PNAd correlates strongly with induction of transcripts for both
GlcNAc6ST-1 and GlcNAc6ST-2, as well as the expression of GlcNAc6ST-2 protein.
Conclusion: Our results demonstrate that PNAd and the sulfotransferases GlcNAc6ST-1 and 2
are induced in mouse collagen-induced arthritis and suggest that PNAd antagonists or inhibitors of
the enzymes may have therapeutic benefit in this widely-used mouse model of RA.
Background
Chronic inflammatory diseases such as rheumatoid
arthritis (RA), asthma, inflammatory bowel disease (IBD),
and multiple sclerosis still pose a large unmet medical
need despite recent therapeutic advances such as inhaled
steroids (asthma) or TNFα antagonists (RA and IBD).
Thus, significant subpopulations of patients, in particular
those with severe disease, respond only poorly to these
treatments [1,2]. Furthermore, patients treated with TNFα
antagonists are at risk for serious infections [3]. Therefore,
modulation of leukocyte-endothelial adhesion, an oblig-
atory step in the recruitment of inflammatory cells to
lesions, has been widely considered as an alternative and
perhaps complementary approach for therapy of chronic
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inflammation [4,5]. One of the molecules involved in leu-
kocyte trafficking is L-selectin, a member of the selectin
family of cell adhesion molecules, which is expressed on
leukocytes [6]. During the process of lymphocyte homing
to lymph nodes, L-selectin mediates rolling of lym-
phocytes on high endothelial venules (HEV). This is the
first step in a cascade of adhesion and signaling events
that culminate in the recruitment of both naïve and cen-
tral memory lymphocytes into lymph nodes [7]. The
major class of ligands recognized by L-selectin consists of
a family of sialomucins defined by the adhesion-blocking
antibody known as MECA-79. Collectively these ligands
are termed peripheral node vascular addressin (PNAd) [8]
or sulfoadhesin [9]. One of the shared features of these
ligands is 6-O-sulfated N-acetylglucosamine, which is
essential for antibody as well as L-selectin binding [10-
12]. This modification is found on 6-sulfo sLex which is a
minimal recognition determinant for L-selectin [13,14].
The 6-O-sulfation of N-acetylglucosamine of PNAd com-
ponents occurs in the Golgi compartment and is catalyzed
by Golgi-associated N-acetylglucosamine 6-O-sulfotrans-
ferases (GlcNAc6STs) [15-17]. Using gene deletion by
homologous recombination in mice, we have shown that
GlcNAc6ST-2, the high endothelial cell restricted N-
acetylglucosamine 6-O-sulfotransferase also known as
HEC-GlcNAc6ST, LSST, or GST-3 (gene name chst4  in
mouse) is largely responsible for the GlcNAc-6-sulfation
of PNAd and contributes substantially to L-selectin ligand
activity and MECA-79 reactivity [18,19]. A related enzyme
known as GlcNAc6ST-1 or GST-2 [20] (gene name chst2)
also contributes to sulfoadhesin biosynthesis but to a
lesser degree [17,21,22].
While being constitutively expressed in the HEV of lymph
nodes and other secondary lymphoid organs, the induc-
tion of PNAd has been reported in activated vessels in syn-
ovial biopsies from RA patients [23-26], in a model of
Lyme disease arthritis in severe combined immunodefi-
cient (SCID) mice infected with Borrelia burgdorferi (B.
burgdorferi) [27], as well as in many other inflammatory
lesions [28]. In addition, extralymphoid induction of
PNAd in inflammatory lesions was shown to correlate
with the de novo expression of GlcNAcST-2 in human RA
[25] as well as animal models of autoimmunity [16,29].
These findings suggested, that blockade of PNAd, either
directly, or indirectly through inhibition of the responsi-
ble sulfotransferase(s), might be efficacious for anti-
inflammatory therapy [30]. As any drug discovery effort
relies on robust and predictive animal models, we have
studied the expression of sulfoadhesin and GlcNAc6ST-1
and -2 in murine collagen-induced arthritis (CIA), a
widely used animal model which is predictive for thera-
peutic benefit in human rheumatoid arthritis [31-33].
Our data show that PNAd is expressed in this model in
arthritic but not in healthy synovial tissue, and that
GlcNAc6ST-1 and 2 are induced in arthritic synovium at
the transcript level for both enzymes and at the protein
level for at least GlcNAc6ST-2.
Results
GlcNAc6ST-1 and -2 transcript are upregulated in arthritic 
but not in normal synovium
In order to investigate the potential relevance of
GlcNAc6ST-1 and -2 in the CIA model, we compared the
expression of transcripts for these enzymes in arthritic and
control synovial tissue by quantitative PCR. We also meas-
ured transcripts levels for genes whose expression is
known to be upregulated in this model (IL-1β and IL-10)
as well as transcript levels for GAPDH, a house keeping
gene whose expression does not change in diseased joints
[34]. All expression data were normalized to GAPDH lev-
els (% of GAPDH expression). As shown in Fig. 1,
GlcNAc6ST-2 transcripts and to a lesser degree
GlcNAc6ST-1 transcripts were upregulated in diseased
joints compared to control joints at all three time points
examined. The mean fold-induction of GlcNAc6ST-2 and
GlcNAc6ST-1 in diseased joints as compared to normal
joints (all time points pooled) was 11-fold and 6-fold,
respectively (p < 0.0005). Although levels of GlcNAc6ST-
2 transcripts in arthritic joints trended to be higher at day
15 than on day 3 or 9, this difference was not statistically
significant. Levels of inflammatory cytokines IL-1β and
IL10 were also elevated in diseased as compared to control
joints (80-fold and 7-fold, respectively) in agreement with
previous reports [35].
Expression levels of GlcNAc6ST-1 (ST-1) and GlcNAc6ST-2  (ST-2) in arthritic versus control joints in mouse CIA Figure 1
Expression levels of GlcNAc6ST-1 (ST-1) and 
GlcNAc6ST-2 (ST-2) in arthritic versus control joints 
in mouse CIA. * p < 0.05, ** only one data point for nor-
mal. Error bars represent standard deviations.BMC Immunology 2006, 7:12 http://www.biomedcentral.com/1471-2172/7/12
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PNAd is induced in arthritic but not in control synovium
We also probed for presence of PNAd in arthritic and nor-
mal synovium by performing immunofluorescence (IF)
on cryostat-cut sections of synovial tissue removed from
arthritic and control healthy joints (knees and ankles).
Five sections were processed from each animal. As shown
in Fig. 2, PNAd was strongly induced in a subset of vessels
in arthritic synovium. These vessels co-stained with an
antibody to CD31, a marker for vascular endothelium
[36]. Normal tissue showed CD31+ vessels, but there was
no reactivity of any of the vessels with MECA-79. Frequent
PNAd+ vessels were observed in diseased synovium at all
three time points, with staining intensity being slightly
higher at day 3 as compared to day 15.
GlcNAc6ST-2 is induced in PNAd+ vessels in arthritic 
synovium
Biosynthesis of the MECA-79 epitope (defining PNAd) in
lymph node HEV depends on GlcNAc6ST-2 and to a lesser
degree on GlcNAc6ST-1 [18,21,22]. The expression of
PNAd in HEV-like vessels within ectopic lymphoid tissue
and inflammatory lesions is associated with co-expression
of GlcNAc6ST-2 and in at least one site, requires this
enzyme [29,37]. Since we had detected PNAd+ vessels in
arthritic synovium (Fig. 2), we probed for GlcNAc6ST-2
protein in these vessels using a peptide-based antibody
[29]. As shown in Fig. 3, GlcNAc6ST-2 was present in a
punctuate Golgi-like pattern in PNAd+ vessels, whereas
GlcNAc6ST-2 protein was not detected in synovium from
control animals (data not shown).
While in Figure 3 all of the vessels stained by MECA-79
also show at least one instance of punctuate Golgi-stain-
ing with the antibody to GlcNAc6ST-2, in other sections
we observed a few vessels that exhibited punctuate
GlcNAc6ST-2 staining in the absence of MECA-79 reactiv-
ity (data not shown). We also noted such a subset of
GlcNAc6ST-2 positive but MECA-79 negative vessels in
biopsies from human RA patients [25]. As MECA-79 reac-
tivity depends not only on GlcNAc 6-O-sulfation but also
on glycosyltransferases, such as the core 1 extension
enzyme [38], such structures perhaps reflect a subset of
"immature" vessels, which lack additional requirements
for recognition by the MECA-79 antibody.
Discussion
PNAd-expressing vessels, which often feature HEV mor-
phology, have been reported to occur at sites of chronic
inflammation (reviewed in references [6] and [28]),
where they are believed to facilitate L-selectin-mediated
recruitment of naïve and central memory lymphocytes
and possibly other leukocytes to the lesions. Significantly,
the presence of PNAd has been shown in synovial vessels
in human RA [23-26] as well as in a model of Lyme dis-
ease arthritis in SCID mice [27]; however, its role in dis-
ease processes is unknown. Other than correlative
histological evidence, there has been one report implicat-
ing L-selectin in the development of arthritis in an animal
model [39]. However, a recombinant P-selectin antago-
nist, which can also bind to L-selectin, was shown to pro-
vide protection in the mouse CIA model [40].
Towards the objective of elucidating novel targets for RA
therapies, the present study examined the expression of
PNAd, and the sulfotransferases, which are involved in its
elaboration, in a model of CIA. This model has proven to
be predictive for therapeutic benefit in human disease
[32].
Using the sulfation-dependent specific antibody MECA-
79 in IF, we found PNAd expressed on a large number of
synovial vessels in arthritic joints at three evenly spaced
time points during the 15 day model but never on syno-
vial vessels from healthy control joints. Furthermore,
most of the PNAd+-positive vessels demonstrated a punc-
tuate staining pattern for GlcNAc6ST-2 protein, consistent
with a Golgi-localization.
In addition, we showed by quantitative PCR that tran-
scripts encoding GlcNAc6ST-2, as well as for the related
sulfotransferase GlcNAc6ST-1, were significantly upregu-
Induction of PNAd in arthritic synovium at day 3 Figure 2
Induction of PNAd in arthritic synovium at day 3. Sec-
tions of knee or ankle joint synovial tissue (obtained at days 
3, 9, and 15) and control tissue (from same times and joints) 
were stained with a CD31 antibody (Cy-2, green), MECA-79 
(Cy3, red) and with hematoxylin for bright field visualization. 
The depicted two-color fluorescence micrographs (400-fold 
magnification) were taken on sections from day 3 and are 
representative for the other sections from this time. Sections 
from days 9 and 15 of the model stained similarly; however, 
the staining intensity with MECA-79 and the fraction of ves-
sels staining with MECA-79 appeared to be somewhat less 
than in sections from day 3 (quantitative image and statistical 
analysis was not performed).BMC Immunology 2006, 7:12 http://www.biomedcentral.com/1471-2172/7/12
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lated in rheumatoid synovium as compared to healthy
control tissue at all time points examined.
Our data demonstrate for the first time that de novo
expression of PNAd together with induction of the
endothelial sulfotransferases GlcNAc6ST-1 and -2 are
associated with disease in the collagen-induced arthritis
model, an established animal model of rheumatoid
arthritis widely used in preclinical development of dis-
ease-modifying anti-rheumatic drugs (DMARDs). While
potential roles of PNAd, as well as GlcNAc6ST-2, in RA
have been considered before [25], it remains unclear,
whether de novo expression of MECA-79-reactive ligands
is causal rather than corollary to the disease process in RA.
Significantly, Salmi and colleagues observed MECA-79+
vessels in human arthritic joints; yet, because of the anti-
body's inability to significantly inhibit binding of acti-
vated mucosal immunoblasts to these vessels, the authors
concluded that MECA-79-reactive ligands contributed lit-
tle to disease-associated leukocyte recruitment [26]. In
arthritic joints of SCID mice infected with B. burgdorferi,
Schaible and coworkers observed the appearance of PNAd
only late during infection following early upregulation of
other adhesion molecules such as P-selectin, VCAM-1 and
ICAM-1 [27]. Therefore these authors hypothesize that
migration of leukocytes to inflamed joints in this model
depends primarily on P-selectin-mediated rolling with
subsequent engagement of α4β1/VCAM-1 and LFA-1/
ICAM-1. However, we have recently demonstrated the
pathophysiological significance of PNAd+  vessels in a
sheep model of bronchial asthma. Intravenous injection
of MECA-79 prior to allergen challenge substantially
blocked increases in airway resistance and airway hyperre-
sponsiveness in allergic animals [41]. Use of the MECA-79
antibody in mouse in vivo models would be hampered by
the very poor half-life of this rat IgM in the mouse circula-
tion (S. Hemmerich, unpublished observations). Never-
theless, the observed induction of PNAd in the mouse CIA
model should motivate alternative approaches to investi-
gate the pathophysiological role of PNAd in RA. Recently,
mice have become available which have the GlcNAc6ST-1
gene, the GlcNAc6ST-2 gene, or both inactivated
[18,21,22]. The double-null mouse exhibits a complete
loss of PNAd from lymph node HEV and a marked but not
complete reduction of L-selectin ligand activity. Breeding
of this mouse line onto a CIA-susceptible background
such as B10RIII or DBA/J [33], should permit investiga-
tion of the contribution of PNAd to disease. Alternatively,
the availability of an IgG-based antibody with a specificity
related to MECA-79 but having improved pharmacokinet-
ics would allow an antibody intervention approach to CIA
in the mouse or other species. We and others have recently
embarked on discovery of GlcNAc6ST and other sul-
fotransferase inhibitors by high throughput screening and
rational drug design (reviewed in references [30], [42] and
[43]). As the CIA model has become the most widely used
preclinical animal model for DMARD development [31],
positive proof of concept achieved in the target-validation
studies discussed above might motivate the development
of GlcNAc6ST inhibitors for disease-modifying treatment
of RA in humans.
Conclusion
MECA-79 binding glycoproteins defined as PNAd serve as
ligands for L- selectin during the process of lymphocyte
homing to lymph nodes. This class of ligands is also criti-
cal for inflammatory leukocyte trafficking and the associ-
ated disease, as recently demonstrated in a sheep model of
asthma. Previous studies in mice have shown the require-
ment for the sulfotransferases GlcNAc6ST-1 and -2 in gen-
erating the MECA-79 epitope and the associated L-selectin
ligand activity in HEV and HEV-like vessels. Immunohis-
tochemical analyses have demonstrated ectopic expres-
sion of PNAd and GlcNAc6ST-2 in human rheumatoid
arthritis. Further investigation into the functional role of
PNAd and the requisite sulfotransferases in RA require a
suitable animal model. Here we show, that PNAd is
expressed de novo in synovial vessels in arthritic joints but
not healthy control joints in the CIA model in mice. We
further demonstrate that GlcNAc6ST-1 and GlcNAc6ST-2
transcripts are strongly upregulated in diseased tissue in
this model and GlcNAc6ST-2 protein is present in a Golgi-
associated pattern in the same vessels that show ectopic
PNAd expression. Our data suggest the CIA model in mice
Induction of GlcNAc6ST-2 in PNAd+ vessels in arthritic syn- ovium at day 3 Figure 3
Induction of GlcNAc6ST-2 in PNAd+ vessels in 
arthritic synovium at day 3. Sections of knee or ankle 
joint synovial tissue (obtained at days 3, 9, and 15 of the 
model) were stained with MECA-79 (Cy3, red), a GlcNAcST-
2 antibody (Cy2, green) and with hematoxylin for bright field 
visualization. The depicted two-color fluorescence micro-
graphs (400-fold magnification) were taken on sections from 
day 3 after disease onset and are representative for the other 
sections from this time. Staining patterns observed on sec-
tions from day 9 and day 15 were very similar to those from 
day 3.BMC Immunology 2006, 7:12 http://www.biomedcentral.com/1471-2172/7/12
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for future studies into the functional role of PNAd-medi-
ated leukocyte recruitment in RA and motivate the evalu-
ation of PNAd antagonists or GlcNAc6ST inhibitors for




The preparation of MECA-79 antibody and the peptide
antibody against mouse GlcNAc6ST-2 are described else-
where [29,41]. Control rat monoclonal IgM JG10.3 was a
gift from Dr. Eugene Butcher (Stanford University). Rat
anti mouse CD31 IgG2a (MEC13.3) and control rat IgG2a
were from BD-Biosciences Pharmingen (San Diego, CA).
Control rabbit IgG was from Sigma.
Arthritis study
Animals
18 Male B10RIII mice (Jackson Labs, Bar Harbor, ME), 8
± 1 weeks on arrival, at least 8 weeks at time of first immu-
nization.
Study design and treatment groups
The in vivo study was carried out in its entirety at Bolder
BioPATH, Boulder, CO. The study protocol was approved
by Bolder BioPATH's Animal Care and Use Committee.
Animals (2/group for arthritis, housed 1–2/cage, were
acclimated for enough days after arrival to ensure that all
mice were at least 8 weeks old. Disease group animals
were anesthetized with isoflurane and injected intrader-
mally with 200 μg bovine type II collagen (Elastin Prod-
ucts, Owensville, MO) emulsified in 100 μl Freund's
complete adjuvant (Sigma-Aldrich, St. Louis, MO) with
supplemental desiccated Mycobacterium tuberculosis H37
Ra (4 mg/ml, Difco Laboratories, Detroit, MI), while nor-
mal control group animals were un-manipulated. On
days 21–26, onset of arthritis occurred and mice were ran-
domized into groups (Table 1), once swelling was obvi-
ously established in at least one paw/joint. Animals were
sacrificed and processed for necropsy as specified in Table
1.
Necropsy/processing of joints
At necropsy, samples of joint tissue were taken from
Groups 1 through 12. Synovium was removed from the
outside of the affected joints with periarticular skin (pri-
marily knee and ankle). Synovium from around the
patella of affected knees was also taken when possible.
Additionally, individual digits showing clinical signs of
arthritis were taken whole. All knee and ankle joints that
had synovium samples removed were stored in 10% neu-
tral buffered formalin for use in histology. Synovium
specimens from Groups 1, 2, 5, 6, 9, and 10, which were
chosen for TaqMan Q-PCR expression profiling, were
snap frozen and shipped to Thios Pharmaceuticals. Syn-
ovium specimens from Groups 3, 4, 7, 8, 11, and 12 were
snap-frozen in a "Gentle Jane" snap freezer (Alphelys,
Plaisir, France) and stored at -70°C for Cryostat section-
ing (10 slides per animal). Frozen sections were shipped
on dry ice to Thios Pharmaceuticals for IF.
Gene expression profiling by TaqMan real time 
polymerase chain reaction (Q-PCR)
The Taqman Q-PCR primers and probes (Table 2) for
mouse GlcNAc6ST-1 and -2 were designed with Primer-
Quest [44] and custom-ordered from Integrated DNA
Technologies (Coralville, IA). The PCR efficiency and spe-
cificity of the primers was tested at the Genome Analysis
Core Facility at the UCSF Comprehensive Cancer Center
(San Francisco, CA) prior to use in the experiments.
Prior to processing, synovia from both inflamed and con-
trol tissues designated for Q-PCR were brought to -20°C
in RNA later-ICE (Ambion, Austin, TX) overnight, and
homogenized with Tissuemiser (Fisher Scientific, Pitts-
burgh, PA) in Trizol (Invitrogen, Carlsbad, CA). Total
RNA was isolated with Trizol following the manufac-
turer's instruction. Each cDNA was reverse transcribed
from 0.5 μg total RNA (random hexamer priming) using
the SuperScript III Platinum Two-Step qRT-PCR kit (Invit-
rogen) according to the manufacturer's instructions.
Quantitative RT-PCR (40 cycles, 15 sec at 95°C, 30 sec at
52°C, 30 sec at 72°C, 1 sec at 82°C, read) was performed
in triplicate at the Genome Analysis Core Facility at the
UCSF Comprehensive Cancer Center using an ABI PRISM
7700 Sequence Detection System (ABI Biosystems, Foster
City, CA). All data were normalized to the level of GAPDH
transcripts in the same sample. The differences were con-
sidered significant when p < 0.05 (Student's T-test).
Immunofluorescence on synovial tissue sections
Frozen tissue sections received on dry ice from Bolder Bio-
PATH were thawed and brought to room temperature (5
sections per animal). The slides were fixed in ice-cold
(0°C) acetone for 5 minutes, and then air-dried at ambi-
ent temperature for 30 minutes. Prior to staining, each tis-
sue section was blocked with 5% mouse serum plus 3%
bovine serum albumin in phosphate-buffered saline
(blocking buffer). All antibodies were diluted in blocking
buffer. The working concentration of primary antibodies
(MECA-79, anti GlcNAc6ST-2 and anti CD31 and the cor-
responding isotype-matched control antibodies) was 1
μg/ml in all cases. Cy2 or Cy3 labeled secondary antibod-
ies and streptavidin (Jackson ImmunoResearch Laborato-
ries, West Grove, PA) were diluted according to the
manufacturer's recommendations. All slides were double-
stained either with MECA-79 and CD31 antibodies or
MECA-79 and GlcNAc6ST-2 antibodies. PNAd expression
was visualized with Cy3-labeled (red) goat anti-ratIgM
while CD31 expression was visualized with Cy2-labeledBMC Immunology 2006, 7:12 http://www.biomedcentral.com/1471-2172/7/12
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(green) goat anti-ratIgG. GlcNAc6ST-2 expression was vis-
ualized with biotinylated goat anti-rabbit IgG followed by
Cy2-labeled streptavidin. Two washings with phosphate
buffered saline (PBS) were performed after each antibody
incubation. Thereafter, slides were lightly counterstained
for 2 seconds with Harris's hematoxylin and mounted
with Fluosave (Calbiochem, San Diego, CA). Slides were
examined under a Zeiss AxioVert200 microscope and
images captured using AxioVision4 software (Carl Zeiss
MicroImaging, Inc., Thornwood, NY).
Abbreviations
B. burgdorferi, Borrelia burgdorferi; CIA, collagen-induced
arthritis; DMARD, disease-modifying anti-rheumatic
drug; GlcNAc6ST, N-acetylglucosamine 6-O-sulfotrans-
ferase; HEV, high endothelial venules; IBD, inflammatory
bowel disease; IF, immunofluorescence; PNAd, peripheral
node vascular addressin; Q-PCR, quantitative polymerase
chain reaction; RA, rheumatoid arthritis; SCID mice,
severe combined immunodeficient mice.
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